Inflammatory Cardiometabolic Risk

Compared with the systemic calcineurin inhibitor standard cyclosporine, tacrolimus shows promise for numerous dermatologic conditions, whereas the literature on voclosporin is limited, according to a study.

Patients with psoriasis taking apremilast saw a 5% to 6% decrease in subcutaneous and visceral adiposity, indicating that the drug may benefit cardiometabolic health, according to a study.

Immunosuppressive therapy for virus-negative inflammatory cardiomyopathy was associated with reduced CV mortality and need for transplantation and persistent improvements in left ventricular function, researchers reported.